secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001564590-21-056413
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon Q3 net loss of $9.8M ($0.66/sh); pipeline progress in ALS, IgAN, transplant
--------------------------------------------------------------------------------

- Net loss of $9.8M for Q3 2021 vs $6.1M; R&D expenses surged to $7.7M from $0.6M.
- Cash of $94.0M as of Sept 30, 2021; company funded into 2023.
- Phase 2 ALS study nearing full enrollment; topline data expected 1H 2022.
- IND clearance for AT-1501 in islet cell transplantation; kidney and IgAN trials expected Q4 2021 start.
- Research collaboration with CareDx for renal transplant biomarkers and predictive algorithms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000156459021056413/0001564590-21-056413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000156459021056413/eldn-8k_20211111.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer